aspirin has been researched along with Neuroendocrine Tumors in 4 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "FH of colorectal cancer (CRC) (8." | 1.43 | Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. ( Campana, D; Capurso, G; Cicchese, N; Delle Fave, G; Falconi, M; Fazio, N; Panzuto, F; Partelli, S; Rinzivillo, M; Spada, F; Tomassetti, P, 2016) |
| "Treatment with aspirin suppressed the viability/proliferation of BON1, NCI-H727 and GOT1 cells in a time- and dose-dependent manner." | 1.40 | Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. ( Auernhammer, CJ; Göke, B; Maurer, J; Spampatti, M; Spöttl, G; Vlotides, G, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalcoli, F | 1 |
| Pusceddu, S | 1 |
| Zilli, A | 1 |
| Tamagno, G | 1 |
| Femia, D | 1 |
| Prinzi, N | 1 |
| Travers, J | 1 |
| Consonni, D | 1 |
| Ciafardini, C | 1 |
| Conte, D | 1 |
| Massironi, S | 1 |
| Manoharan, J | 1 |
| Fendrich, V | 1 |
| Di Fazio, P | 1 |
| Bollmann, C | 1 |
| Roth, S | 1 |
| Joos, B | 1 |
| Mintziras, I | 1 |
| Albers, MB | 1 |
| Ramaswamy, A | 1 |
| Bertolino, P | 1 |
| Zhang, CX | 1 |
| Slater, EP | 1 |
| Bartsch, DK | 1 |
| Lopez-Lopez, CL | 1 |
| Spampatti, M | 1 |
| Vlotides, G | 1 |
| Spöttl, G | 1 |
| Maurer, J | 1 |
| Göke, B | 1 |
| Auernhammer, CJ | 1 |
| Rinzivillo, M | 1 |
| Capurso, G | 1 |
| Campana, D | 1 |
| Fazio, N | 1 |
| Panzuto, F | 1 |
| Spada, F | 1 |
| Cicchese, N | 1 |
| Partelli, S | 1 |
| Tomassetti, P | 1 |
| Falconi, M | 1 |
| Delle Fave, G | 1 |
4 other studies available for aspirin and Neuroendocrine Tumors
| Article | Year |
|---|---|
Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Disease Progression; F | 2019 |
Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model.
Topics: Animals; Aspirin; Chemoprevention; Enalapril; Mice; Mice, Knockout; Multiple Endocrine Neoplasia Typ | 2018 |
Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.
Topics: Antineoplastic Agents; Aspirin; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell | 2014 |
Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Colorectal Neoplasms; Fem | 2016 |